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EPIDEMIOLOGY
Chicken pox (varicella) is erroneously
regarded as a trivial, self-limited infection
of children.While the death rate in chil-
dren is below 2/100 000, it rises more
than 15-fold in adults.1 Prior to the intro-
duction of antiviral medication, the mor-
tality rate in leukaemic children was 7%, 3
500-fold higher than in immunocompe-
tent children.2
Ninety per cent of cases of chicken pox
occur in children younger than 13 years of
age. However, 10% of adolescents and
adults are still susceptible to varicella. For
example, Waner showed that 10% of med-
ical students attending the University of
the Witwatersrand were susceptible.3
PATHOGENESIS
Chicken pox is caused by the varicella
zoster virus (VZV) and is closely related
to herpes simplex, that causes cold sores
and genital ulcers. An important charac-
teristic of VZV is that it is very efficiently
spread by airborne microscopic droplets
or by contact with infected secretions. The
incubation period usually varies from 14
to 16 days although the range is 10 - 21
days. In patients who have received vari-
cella zoster immunoglobulin (VZIG), the
incubation period is extended to 28 days.
NATURAL HISTORY
Varicella usually presents with a short
history of fever for 1 or 2 days followed by
crops of skin lesions on the trunk.The
skin lesions characteristically start as red
spots, rapidly become vesicles (blisters)
and then form crusts. The rash is often
very itchy. The blisters are described as
‘dewdrops on petal’. A characteristic fea-
ture of the rash is that at any one time,
the skin lesions will be present in various
stages. Occasionally the blisters occur in
the mouth as well. Usually, by day 3 - 5,
no new blisters are seen. For those inter-
ested in counting blisters, between 250
and 500 lesions are seen in an ‘average’
infection.The child is infectious from the
time of feeling ill until the last blister has
formed a crust. Knowledge of the natural
history of chicken pox is important as any
deviation may suggest life-threatening
complications, where rapid recognition
and early intervention favourably alter the
course of events.
COMPLICATIONS
Large surveys of normal infants and child-
ren show a small but significant rate of
complications. For example, in a recent
German survey of children below 16 years
of age, 8/100 000 had illness severe
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The varicella zoster vaccine
Chicken pox is generally thought of as a trivial
childhood illness. But it can have serious conse -
quences in immunocompromised people. Hence
the importance of the vaccine.
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Prior to the introduction
of antiviral medication,
the mortality rate in
leukaemic children was
7%, 3 500-fold higher
than in immunocompe -
tent children.
enough for hospitalisation.4 The
majority were central nervous sys-
tem sequelae such as postinfective
cerebellar ataxia that resolved with-
out sequelae. However, secondary
bacterial infections due to
Staphylococcus aureus and
Streptococcus pyogenes were respon-
sible for more than a third of seri-
ous complications that include
necrotising fasciitis and disseminat-
ed multifocal osteoarthritis. In
adults, varicella pneumonitis and
acute encephalitis are two common
and potentially fatal complications.
In immunocompromised patients,
progressive varicella can occur,
characterised by continuing erup-
tion of lesions and high fever into
the second week of the illness. This
may progress to encephalitis,
hepatitis or pneumonia.
Haemorrhagic chicken pox is also
more common in immunocompro-
mised patients.5
Even the treatment of chicken pox
can be problematic. Where aspirin
is used for temperature control, a
severe and often fatal metabolic
disease called Reye’s syndrome can
occur. This condition manifests as
excessive vomiting and decreased
level of consciousness. Other non-
steroidal anti-inflammatory agents
have also been implicated in com-
plicated varicella.5 For these rea-
sons, only paracetamol should be
used as an antipyretic agent.
There is an appreciable risk for
congenital anomalies when vari-
cella occurs in the first half of
pregnancy. The incidence of con-
genital varicella syndrome follow-
ing from exposure between zero
and 12 weeks is 0.4% and rises to
2% following exposure between 12
and 20 weeks’ gestation.The con-
genital varicella syndrome includes
anomalies such as limb deformi-
ties, scars on the skin and chorio-
retinitis.
Patients at high risk for compli-
cations of chicken pox (Table I)
Pregnant women are at risk for
serious disease. Even more serious
is the risk of severe chicken pox in
newborn infants where the mother
has developed symptoms in the
days just before or after the birth
of the infant.
In patients of all ages with
depressed immunity, chicken pox is
a very serious illness. Individuals
on corticosteroids and cancer
treatment are at especially high
risk. HIV infection is also associat-
ed with severe chicken pox.
VZV VACCINE
Because of the high mortality in
children with cancer, Takahashi
and colleagues developed the
attenuated Oka vaccine strain in
the early seventies.6 This strain was
shown to be safe, effective and
immunogenic in both immuno-
compromised and immunocompe-
tent children and adults.7,8 In the
USA it has been used since 1995
and has caused a dramatic reduc-
tion in hospitalisation due to VZV.
The vaccine was introduced in
South Africa in March 2002. It
may be administered at the same
time as the MMR vaccine, but
must be given at a separate injec-
tion site. If not given with the
MMR, then there should be at
least 4 weeks’ gap between the two
vaccines.
Storage
Storage under optimal conditions
is important, and the ‘cold chain’
should be maintained.The
lyophillised vaccine should be
refrigerated. Once reconstituted,
the vaccine should be administered
within 30 minutes.
Indications for the use of the
varicella vaccine
Indications for the vaccine’s use
are shown in Table II and cover
both immunocompetent and
immunodeficient patients. Because
varicella causes a trivial disease in
the majority of children, there is
some debate as to whether all chil-
dren should receive the vaccine or
whether it should be reserved for
high-risk situations. In USA, the
vaccine is recommended for all
infants at 12 months of age. Its use
has been associated with a steady
drop in hospitalisations due to
chicken pox.9 Cost benefit analyses
favour widespread use of the vac-
cine.10 Regrettably, the vaccine is
not yet an option in public clinics
in South Africa because of cost
constraints.
Another argument against the use
of the vaccine is concern that the
duration of protection after the
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• Pregnant women
• Neonate born to woman who
develops varicella between 5





• Patients taking corticos-
teroids during the incubation
period of varicella (2
mg/kg/day)




There is no evidence
that immunisation
during the incuba -
tion period exacer -
bates the clinical
c o u r s e .5
vaccine may be less than that of
‘natural’ chicken pox.There is also
concern that, with gradual intro-
duction of the vaccine and
decreased circulation of the wild
virus, fewer young children will get
chicken pox and will thus be sus-
ceptible when older and at risk for
more severe disease. As mentioned
earlier, a small number of normal
children do get serious complica-
tions following chicken pox.This is
only evident if statistics are collect-
ed at a community level as even in
the experience of individual doc-
tors, few patients with severe dis-
ease are seen.
Post-exposure prophylaxis
VZV vaccine can prevent chicken
pox if given within 72 hours and
possibly up to 120 hours of known
exposure to someone with chicken
pox. If the exposure of the vacci-
nated contact occurred at the same
time as the index patient, chicken
pox may still occur, but this should
not be regarded as a vaccine fail-
ure.There is no evidence that
immunisation during the incuba-
tion period exacerbates the clinical
course.5
The VZV vaccine results in long-
lasting immunity in contrast to
VZIG, which protects for only 2
weeks.
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Immune status Group Dosage Comments
Healthy Infants from 9 months of age* 1 dose If given with measles mumps
rubella (MMR) vaccine, use
separate syringe and site or
give 4 weeks apart
Can be given at same time as 
other vaccines
Adolescents and young adults 2 doses 4 - 8
Adults — give priority to: weeks apart
• Settings where VZV exposure  
is likely (teachers, day care 
workers)
• Settings where rapid spread is 
likely (military, correctional 
facilities, students)
• non-pregnant women of 
childbearing age
• adolescents and adults in 
households with susceptible 
children
Immunocompromised Acute lymphocytic leukaemia In maintenance phase (with-
hold therapy in preceding 
week)
Lymphocyte count > 0.7 X 
109/l (children) and > 1200 X 
109/l in adults and platelet 
count > 100 X 109/l
HIV infection in children 2 doses 3 months CD4 percentage 
(no recommendation for adults) apart > 25%
Corticosteroids If receiving < 2mg/kg/day or 
20 mg/day if body weight 
>10 kg
If on higher dose for 14 days, 
reduce dosage & immunise 
after 1 month
*In USA vaccination is recommended from 12 months.
Table II. Indications for and frequency of adminstration of Varicella zoster 
vaccine
Should older patients routinely
undergo serological testing prior
to immunisation?
Serological testing is unnecessar y
in patients with a reliable history of
chicken pox and between 70% and
90% of adults without a reliable
history will also be immune. It may
be cost-effective to screen adults
with an unreliable history, but this
will involve an extra health care
visit.
Vaccine efficacy
The vaccine is 85 - 90% effective
in preventing varicella during an
outbreak and 100% effective at
preventing severe disease. ‘Break
through’ varicella does occur in a
small percentage of vaccinees, but
is generally extremely mild with
very few vesicles, which may be
mistaken for insect bites.
How long does immunity last
after VZV vaccine administra-
tion?
Studies from Japan show protec-
tion for 20 years and in the USA
for 11 years. However, presence of
wild-type varicella in the commu-
nity may play a role by boosting
immunity.This phenomenon
would be expected to decline with
more widespread use of the vac-
cine. Additional follow-up studies
are necessary, although other live
virus vaccines such as measles and
rubella do give life-long immunity.5
Adverse events
Minor injection site reactions are
common. A mild localised or gen-
eralised varicella-like eruption
occurs in 3 - 5% of children within
4 weeks of receiving the vaccine.
More serious short-term events
have been rarely reported and diffi-
cult to link causally to the vaccine.
In the longer term, the varicella
vaccine can cause shingles in both
immunocompetent and immuno-
compromised persons but this
appears to occur at a much lower
rate than shingles following natural
varicella infection.
Contraindications
The vaccine should not be given to
any significantly immunocompro-
mised person (see Table II for
guidelines). Transmission of the
vaccine virus from a vaccinee to
susceptible individuals is an
extremely rare event and the virus
remains attenuated so that an
immunocompromised household
member is not a contraindication
to vaccination.
As with all live virus vaccines,
pregnant women should not be
immunised and pregnancy should
be excluded before immunising
women of childbearing age.
Women should avoid conception in
the month after vaccination.The
manufacturer of the vaccine and
the Centers for Disease Control,
USA, jointly maintain a registry for
women inadvertently immunised
during pregnancy. There is also a
theoretical risk of transferring virus
through breast milk but a breast-
feeding mother should be immu-
nised if there is chicken pox expo-
sure.
The vaccine should not be given to
persons who have had anaphylac-
tic-type reactions to constituents of
the vaccine, including gelatin and
neomycin.
CONCLUSION
Varicella has not received appropri-
ate recognition as a serious disease
in South Africa.The VZV vaccine
represents a major advance in clini-
cal care. Cost constraints are a
serious impediment to widespread
use.
References available on request.
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IN A NUTSHELL
Although chicken pox is regarded
as a trivial infection of childhood,
it can have serious consequences
in immunocompromised patients,
all adolescents and adults, and in
a minority of immunocompetent
children.
For HIV infection, at present, a
CD4 percentage > 25% is recom-
mended before vaccination.
The varicella vaccine, consisting
of live attenuated virus, is safe
and effective.
It can be given to infants from 9
months of age, but is probably
better to give at 12 months.
All susceptible adults and adoles-
cents should be immunised, espe-
cially where the risk of contact is
high (health care and day care
workers and parents with young
children).
The vaccine is effective as post-
exposure prophylaxis if given
within 72 hours of exposure.
Minor injection site
reactions are 
c o m m o n .
Varicella has not
received appropri -
ate recognition as a
serious disease in
South Africa.
